Perfect Medical Health Management Limited Announces Extraordinary General Meeting and Major Share Option Scheme Changes
Key Points and Investor Highlights
- Extraordinary General Meeting (EGM) Scheduled: Perfect Medical Health Management Limited will hold its EGM on Thursday, 18 June 2026 at 4:00 p.m. at Conference Room 1, 49/F, Langham Place Office Tower, Mong Kok, Hong Kong.
- Adoption of New 2026 Share Option Scheme: The company is seeking shareholder approval for a new 2026 Share Option Scheme, which will replace the existing scheme adopted in 2021.
- Share Issuance Cap: Under the proposed 2026 Share Option Scheme, the total number of shares that can be allotted and issued (including under other share schemes) will be capped at 4.10% of the company’s issued shares as of the date of resolution approval, excluding any treasury shares.
- Termination of Existing Share Option Scheme: Conditional on the new scheme becoming effective, the existing share option scheme adopted on 13 August 2021 will be terminated with immediate effect.
- Significant Grant to Chairman: Conditional approval is sought to grant 50,000,000 share options to Dr. Au-Yeung Kong, the Chairman, under the new scheme at an exercise price of HK\$1.184 per share, as detailed in the shareholder circular dated 2 June 2026.
- Board Authorization: Directors are to be empowered to administer, amend, and implement the 2026 Share Option Scheme, including applying for share listings and handling regulatory requirements.
- Key Dates for Shareholders: Share registration will be closed from 15 June 2026 to 18 June 2026 (both dates inclusive). Only shareholders registered by 4:30 p.m. on 12 June 2026 will be eligible to attend and vote at the EGM.
Detailed Analysis and Price-Sensitive Information
The proposed 2026 Share Option Scheme represents a significant move by Perfect Medical Health Management Limited to align employee and management incentives with shareholder interests. The cap of 4.10% ensures that potential dilution to existing shareholders is limited. However, the sizeable grant of 50,000,000 options to the Chairman, Dr. Au-Yeung Kong, at a set price of HK\$1.184 per share, could be viewed as a strong incentive for management to drive future performance, but may also raise concerns about dilution and the balance of power within the company.
Shareholders and investors should pay close attention to the potential impacts of these resolutions:
- The large option grant to the Chairman may be seen as a vote of confidence in leadership, but could also be interpreted as consolidating executive influence.
- The introduction of the new scheme and concurrent termination of the old may affect the company’s compensation structure and could impact share price depending on investor sentiment regarding dilution and management incentives.
- Eligibility to participate in the EGM and vote on these resolutions requires shareholders to ensure their shares are registered by 12 June 2026, which may influence near-term trading volumes and price movements.
If approved, the new scheme authorizes the Board to make further amendments and handle all necessary regulatory and procedural steps, providing flexibility in its implementation.
Board and Governance
The Board is comprised of both executive and independent non-executive directors, with Dr. Au-Yeung Kong as Chairman. The company explicitly outlines the procedures for proxy voting, joint shareholding, and registration, ensuring transparency and shareholder engagement.
Action Required by Shareholders
- Review the circular and proposed resolutions in detail.
- Ensure share registration is complete by the deadline if wishing to vote.
- Consider the implications of the new share option scheme, particularly the allocation to executive management, on future share value and governance.
Potential Share Price Impact
The approval and adoption of the new share option scheme, especially the large option grant to the Chairman, is potentially price-sensitive. Investors should monitor market reactions closely as these developments could impact perceptions of corporate governance, dilution, and management incentives.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult professional advisors before making investment decisions.
完美醫療健康管理有限公司公佈股東特別大會及重大股票期權計劃變動
主要重點及投資者須知
- 召開特別股東大會： 完美醫療健康管理有限公司將於2026年6月18日（星期四）下午4時，於旺角朗豪坊辦公大樓49樓會議室1舉行特別股東大會。
- 擬採納2026年新股票期權計劃： 公司尋求股東批准採納新的2026年股票期權計劃，將取代現行於2021年採納的計劃。
- 股票發行上限： 根據新計劃，所有可分配及發行的股份（包括其他計劃下發行的股份）總數將不超過於決議通過當日已發行股份（不包括庫存股）的4.10%。
- 終止現有股票期權計劃： 若新計劃生效，現行於2021年8月13日採納的股票期權計劃將即時終止。
- 主席獲大量期權授予： 擬授予主席歐陽江醫生5,000萬份購股期權，行使價每股HK\$1.184，詳情載於2026年6月2日之股東通函。
- 董事會授權： 董事將被授權管理、修訂及執行新股票期權計劃，包括申請上市及處理監管事項。
- 關鍵股東日期： 2026年6月15日至18日（包括首尾兩日）暫停股份過戶，2026年6月12日下午4:30前完成股份登記，方有資格出席及投票。
詳細分析及潛在影響
擬議的2026年股票期權計劃，標誌著公司激勵機制的重大調整。4.10%的上限可限制現有股東的攤薄風險，但主席獲大額期權授予，既展現對管理層信心，也或會引發對攤薄及權力集中之關注。
股東與投資者應密切留意以下影響：
- 主席獲大額期權可被視為管理層對公司前景有信心，但亦可能引起對權力集中的疑慮。
- 新舊方案更替，或影響公司薪酬結構，進而作用於股價。
- 欲參與投票的股東須確保於截止日前完成股份登記，或影響短期交投及價格波動。
新計劃獲批後，董事會可作出靈活修訂及處理實施細節。
董事會及公司治理
現時董事會由執行及獨立非執行董事組成，主席為歐陽江醫生。公司亦明確列出委託投票、聯名持股及股份登記程序，保障股東權益。
股東應採取的行動
- 詳閱通函及相關決議內容。
- 如欲投票，必須於截止日前完成股份登記。
- 審視新股票期權計劃，特別是對管理層授權的規模及其對未來股份價值和治理的潛在影響。
對股價的潛在影響
新股票期權計劃及主席獲大額授權屬潛在敏感消息，或影響市場對公司治理、攤薄及管理層激勵的看法，投資者應密切關注市場反應。
免責聲明
本文僅供參考，並不構成投資建議。投資者應自行研究或諮詢專業人士後作出投資決定。
